Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Core Insights - Nurix Therapeutics presented multiple preclinical data at the AACR 2025 Annual Meeting, showcasing advancements in targeted protein degradation therapies for cancer treatment [1][2][3] Group 1: Bexobrutideg (NX-5948) - Bexobrutideg, a BTK degrader, can degrade approximately 10,000 copies of BTK per hour, demonstrating high catalytic efficiency [2] - It shows CNS exposure and is detectable in cerebrospinal fluid, indicating potential effectiveness in treating CNS-related cancers [2][6] Group 2: NRX-0305 - NRX-0305 is a pan-mutant BRAF degrader that effectively targets all three classes of BRAF mutations while sparing healthy cells [3][7] - Preclinical data indicate that NRX-0305 has broad anti-tumor efficacy, particularly in tumors resistant to existing therapies [3][7] Group 3: Aurora A Kinase Degraders - Nurix is developing selective, orally bioavailable degraders of Aurora A kinase (AURKA) for treating aggressive childhood cancers [4][5] - Preclinical studies of NRX-4972, an AURKA degrader, show significant efficacy in neuroblastoma models, outperforming traditional AURKA inhibitors [5][8] Group 4: Company Overview - Nurix Therapeutics focuses on the discovery and development of targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [9] - The company utilizes an AI-integrated discovery engine and has collaborations with major pharmaceutical companies for drug development [9]